APPRECIATE: Phase 2 Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE)

The purpose of this study is to learn more about the safety, tolerability, and effectiveness of AZD2373 and to better understand the studied disease, APOL1-Mediated Kidney Disease (AMKD), and associated health problems. People diagnosed with AMKD have a certain change (variant) in the Apolipoprotein L1 (APOL1) gene. The APOL1 gene creates proteins that play a role in immunity. Some people have a variant in the APOL1 gene. APOL1 gene variant is associated with protection against African sleeping sickness. Whilst protecting from one disease, this variant increases the risk of kidney disease in some people. There is currently no approved treatment for AMKD. AZD2373 is being developed as a potential treatment for AMKD. It works by decreasing the production of the APOL1 protein. Participants will undergo physical examinations, vital signs measurements, blood and urine samples collection, Electrocardiograms and completion of questionnaire and a diary.About 96 participants will take part in this study which is being conducted in the United Kingdom and the United States. Participants will be in the study for a minimum of 58 weeks.The study is sponsored by AstraZeneca AB.